Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.
about
Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s DiseaseCholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's diseaseCholinesterase inhibitors for Parkinson's disease dementiaPsychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.Treatment of psychosis and dementia in Parkinson's disease.Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson'Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data.Drug treatment of non-motor symptoms in Parkinson's disease.Sundown syndrome in persons with dementia: an update.Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?Pathophysiology and treatment of psychosis in Parkinson's disease: a review.Parkinson's psychosis.Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort studyBehavioral disturbances in Parkinson's diseasePharmacologic management of psychosis in the elderly: a critical review.Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease.Psychotic symptoms in Parkinson's disease: pathophysiology and management.Rivastigmine in vascular dementia.Psychosis in Parkinson's disease.Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.Treatment of behavioural symptoms and dementia in Parkinson's disease.A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia.Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs.Current strategies for the treatment of Alzheimer's disease and other tauopathies.Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.Intervening in the neuropsychiatric features of Parkinson's disease.Current approaches to the treatment of Parkinson's diseaseRivastigmine in the treatment of Alzheimer's disease: an update.New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins.Mild cognitive impairment in Parkinson's disease: the challenge and the promiseRivastigmine in Parkinson's disease dementia.Diagnosis and management of Parkinson's disease dementia.Rivastigmine for the treatment of dementia associated with Parkinson's diseaseRivastigmine as a Symptomatic Treatment for Apathy in Parkinson's Dementia Complex: New Aspects for This Riddle.Atypical antipsychotic drugs in the treatment of Parkinson's disease.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease.Treating psychosis in movement disorder patients: a review.Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.Psychiatric Conditions in Parkinson Disease: A Comparison With Classical Psychiatric Disorders.
P2860
Q24188194-1F3E94F8-7D0C-44DE-BDDB-11F61DAA9DE5Q24201307-4619467D-E076-4F2F-82EA-8A974364C68BQ24244668-20425FA0-AFF9-41FE-88B2-85C765057D61Q30249553-2D0F1D79-15F5-4007-93F9-C2226655FFB0Q30358337-BB5C08B6-83E2-4790-B798-40320ADA457AQ33260251-B6F1BF2A-32F0-48D4-897F-4C051E0516C4Q34032505-EE634D81-0722-46BB-BDC6-3BDF00D9C7D7Q34122222-66ADB67D-21DC-49C0-8D9A-26789EA47B58Q34244388-163AA702-FFFB-4580-A173-681D5634B26BQ34610593-EE14AC97-2A3B-4D58-A6C8-4E93256481E3Q34610608-CBC6C0CA-9798-4B90-8675-66EBF554E89AQ34610632-0829E34F-F2D6-4876-BC98-FD557ADEE93CQ35016008-0317D6E3-27AD-4F14-9D70-35BDF513DEFDQ35236819-26B98995-1BC9-49B4-B4F6-A71D1DC7D9C6Q35599469-E5E79BDF-1F35-422C-9491-8F9D2E639A31Q35687749-AA7F125B-F898-4C16-9DDA-3E6B9D9C5801Q35779329-2BD5DEFD-30C1-4229-9C0B-5203036777D9Q35784086-76E83430-0F26-4698-9CC4-814E922D5C96Q35863404-F001BE0A-5A3A-4ED4-95D0-5D005FA9485CQ35863422-9D267832-B1CC-4CF7-B805-63A582486ECBQ36089350-18303016-BB8A-4D9A-9A55-85E37CD1B38DQ36118555-CA9A5207-AAF4-4F73-AF5D-987A19DE1502Q36425995-F3CE41DF-E1A8-4D0B-8269-0F4ED2BDE69FQ36596669-7C4684C0-CF30-4577-A91A-D588CFA633E0Q36632771-DFE71EA4-665A-47D7-85E1-54DA33BF36BBQ36847266-4CC439AC-DCF1-42AE-8702-806158DBB675Q36876438-83352822-2754-48A4-B98F-33C2C7A6B9F0Q37017260-78AA6158-8329-4EA2-A1F1-EC6EAF1F9FD1Q37021326-6C70E60C-9CDE-4D25-8D20-FE11A5B7D2FBQ37196144-9C89E877-B870-4236-A585-09E8CCA6122AQ37232006-396D2480-B508-4508-ACB4-35AB3F3A295DQ37281128-222C29F9-881E-40CC-9CCB-368AEA69D7ECQ37418973-0BE5A574-2A82-41C3-8EAA-35E797EFF58EQ37733592-EB8AAF08-B3DA-4A7E-BCA5-9FF9450579D7Q37957772-3AE9E243-0EDB-44DD-827C-9C7DF5F32649Q38070888-D32D9B63-E7A7-42A7-A374-AD6BC438195CQ38111335-B5893EDC-FA1A-462A-9211-8F26EE397856Q38213306-F78CFC3C-BE41-4B6B-8A35-CC9F48E4F033Q38221488-BABE8841-DF38-4C71-8FA9-8B4E6891A3C3Q38588201-FEE438BB-3508-46B1-B605-C9516AB0580D
P2860
Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Rivastigmine in the treatment ...... y findings from an open trial.
@en
Rivastigmine in the treatment ...... y findings from an open trial.
@nl
type
label
Rivastigmine in the treatment ...... y findings from an open trial.
@en
Rivastigmine in the treatment ...... y findings from an open trial.
@nl
prefLabel
Rivastigmine in the treatment ...... y findings from an open trial.
@en
Rivastigmine in the treatment ...... y findings from an open trial.
@nl
P2093
P2860
P356
P1433
P1476
Rivastigmine in the treatment ...... y findings from an open trial.
@en
P2093
P2860
P304
P356
10.1002/MDS.1204
P407
P577
2001-11-01T00:00:00Z